Jordan Ciuro, MD
@jordanciuro
Followers
288
Following
104
Statuses
226
Medical oncologist @WinshipAtEmory, specializing in genitourinary cancer. Editor and TB moderator @themednet.org
Atlanta, GA
Joined September 2017
Reviewing systemic therapy for biochemical recurrence (BCR) in #prostatecancer after local treatment options are exhausted @ASCOGU #GU25 Key Takeaways: ✅Consider PET imaging for guiding metastasis-directed therapy ✅PSA monitoring remains a reasonable approach if PSA doubling time (DT) is >9 months ✅ If PSA DT <9 months, treatment options include ADT + ARPI, ARPI alone, tE2, intermittent ADT, or active monitoring @ASCO @OncoAlert @GUOncologyNow @urotoday @TargetedOnc @OncoReporte @OncLive @CaPsurvivorship
0
0
0
Absolutely agree...identifying which patients benefit most from ARPIs in mHSPC is key to refining treatment strategies. Comparative studies against other intensification strategies, like triplet therapy, continue to evolve and I'm looking forward to more insights. Thanks for sharing the resource!
0
0
0
RT @yekeduz_emre: 🔥Association of baseline and on-treatment ctDNA fraction with clinical outcomes in patients with mCRPC in the PSMAfore st…
0
11
0
OS updates in ENZA-P trial evaluating Lu-PSMA with enzalutamide in 1L mCRPC? #GU25 ✅Improved OS 26m to 34m w/ enza+Lu-PSMA ✅Improved QOL ✅Grade 3-5 AE 44% enza mono vs 46% in combination 📌More data for earlier PSMA therapy!!! Check out publication @TheLancetOncol today! @ASCO @OncoAlert @GUOncologyNow @urotoday @TargetedOnc @OncoReporte @OncLive
1
6
7
Expanding the application of PSMA therapy #GU25 Exciting new data on the horizon. Trials on trials on trial… and even more to come. Check out mechanisms to optimize PSMA theranostics 🔎Work needed on mechanism/resistance in PSMA neg disease 🔎We need to understanding tumor microenvironment 🔎Role of alpha emitters? Combination w/ beta emitters? @ASCO @OncoAlert @GUOncologyNow @urotoday @TargetedOnc @OncoReporte
0
8
11
OS Updates of TALAPRO-2 in 1L mCRPC? #GU25 ✅First PARPi+ARPI showing improved OS: 8.8m longer than control ✅Median rPFS: 13.6m longer in combination arm 📌49% with grade 3-4 anemia 📌8.5% discontinued talazoparib due to anemia @neerajaiims @ASCO @OncoAlert @GUOncologyNow
0
8
16
RT @MikeSerzanMD: 🗣️Prostate Cancer Oral Abstracts #GU25 Dr @Soum_Roy_RadOnc presenting Ab 309: 🔪(RP) versus ⚡️(RT) in high-risk prostate…
0
8
0
Today's the day! 🎉 #GUASCO25 kicks off, and I can't wait for the latest updates in genitourinary cancer! 🔬📢 Check out the abstracts I’m most excited about on @GUOncologyNow , and let me know which ones you're looking forward to this year! 👇🏼✨ #GU25 #Oncology #CancerResearch @WinshipAtEmory @ASCO @ASCOPost @TargetedOnc @OncoAlert @neerajaiims @tompowles1 @kidneycan @BladderCancerUS @PCFnews
⭐ Get ready for the start of @ASCO #GU25 tomorrow by learning about some of the top research to look out for with @jordanciuro! 📺 Dr. Ciuro highlights research in #prostatecancer treatment advancements, emerging therapies in #bladdercancer, and more:
0
0
3
RT @tompowles1: Voluntary withdrawal of sacituzumab govitecan in pretreated advanced bladder cancer occurred today. Accelerated approval re…
0
60
0
RT @montypal: Woke up to this incredible news from the #TALAPRO2 study. Hugely proud of @neerajaiims @huntsmancancer for leading the 1st st…
0
28
0
RT @DrYukselUrun: Huge congratulations to @hatice_bolek and @coskunyazgann for their outstanding work. @yekeduz_emre Cisplatin’s immunomod…
0
30
0
RT @PGrivasMDPhD: Excited to join the awesome @OncBrothers & discuss @myESMO key data on GU cancers! @Uromigos @shilpaonc @montypal @neeraj…
0
5
0
RT @brookmans76: #SWOGS1011 finally published in @NEJM ✅Extended LND in #MIBC did not improve OS/DFS vs. standard LND ✅Higher morbidity/mo…
0
15
0